These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 21787818)
61. Doxorubicin-loaded Polymeric Biotin-PEG-SeSe-PBLA Micelles with surface Binding of Biotin-Mediated Cancer Cell Targeting and Redox-Responsive Drug release for enhanced anticancer efficacy. Gebrie HT; Thankachan D; Tsai HC; Lai JY; Chang HM; Wu SY Colloids Surf B Biointerfaces; 2024 Sep; 241():114028. PubMed ID: 38905811 [TBL] [Abstract][Full Text] [Related]
62. Fine-tuning vitamin E-containing telodendrimers for efficient delivery of gambogic acid in colon cancer treatment. Huang W; Wang X; Shi C; Guo D; Xu G; Wang L; Bodman A; Luo J Mol Pharm; 2015 Apr; 12(4):1216-29. PubMed ID: 25692376 [TBL] [Abstract][Full Text] [Related]
63. 1, 2-Dihexadecanoyl-sn-glycero-3-phosphoethanolamin (DPPE), doxorubicin and folic acid conjugated micelles for cancer management in tumor bearing BALB/c mice. Uttekar PS; Yadav VD; Bhagwat DA Bioorg Med Chem Lett; 2021 Oct; 50():128337. PubMed ID: 34438013 [TBL] [Abstract][Full Text] [Related]
64. mPEGylated solanesol micelles as redox-responsive nanocarriers with synergistic anticancer effect. Qin B; Liu L; Wu X; Liang F; Hou T; Pan Y; Song S Acta Biomater; 2017 Dec; 64():211-222. PubMed ID: 28963017 [TBL] [Abstract][Full Text] [Related]
65. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784 [TBL] [Abstract][Full Text] [Related]
66. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy. Hu FQ; Zhang YY; You J; Yuan H; Du YZ Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551 [TBL] [Abstract][Full Text] [Related]
67. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. Ogawara K; Un K; Tanaka K; Higaki K; Kimura T J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484 [TBL] [Abstract][Full Text] [Related]
68. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939 [TBL] [Abstract][Full Text] [Related]
70. Fine tuning micellar core-forming block of poly(ethylene glycol)-block-poly(ε-caprolactone) amphiphilic copolymers based on chemical modification for the solubilization and delivery of doxorubicin. Yan J; Ye Z; Chen M; Liu Z; Xiao Y; Zhang Y; Zhou Y; Tan W; Lang M Biomacromolecules; 2011 Jul; 12(7):2562-72. PubMed ID: 21598958 [TBL] [Abstract][Full Text] [Related]
72. In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery. Zou A; Chen Y; Huo M; Wang J; Zhang Y; Zhou J; Zhang Q J Pharm Sci; 2013 Jan; 102(1):126-35. PubMed ID: 23073894 [TBL] [Abstract][Full Text] [Related]
73. Surface-Modified Nanoerythrocyte Loading DOX for Targeted Liver Cancer Chemotherapy. Wang Y; Chen X; He D; Zhou Y; Qin L Mol Pharm; 2018 Dec; 15(12):5728-5740. PubMed ID: 30359027 [TBL] [Abstract][Full Text] [Related]
74. In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug. Boddu SH; Jwala J; Chowdhury MR; Mitra AK J Ocul Pharmacol Ther; 2010 Oct; 26(5):459-68. PubMed ID: 20874666 [TBL] [Abstract][Full Text] [Related]
75. Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity. Song YF; Liu DZ; Cheng Y; Liu M; Ye WL; Zhang BL; Liu XY; Zhou SY Sci Rep; 2015 Nov; 5():16125. PubMed ID: 26530454 [TBL] [Abstract][Full Text] [Related]
76. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo. Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029 [TBL] [Abstract][Full Text] [Related]
77. Conjugates of TAT and folate with DOX-loaded chitosan micelles offer effective intracellular delivery ability. Zhang S; Liu Y; Gan Y; Qiu N; Gu Y; Zhu H Pharm Dev Technol; 2019 Feb; 24(2):253-261. PubMed ID: 29688120 [TBL] [Abstract][Full Text] [Related]
78. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo. Gu X; Wei Y; Fan Q; Sun H; Cheng R; Zhong Z; Deng C J Control Release; 2019 May; 301():110-118. PubMed ID: 30898610 [TBL] [Abstract][Full Text] [Related]
79. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx? Zou Y; Meng F; Deng C; Zhong Z J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664 [TBL] [Abstract][Full Text] [Related]
80. Phenylboronic ester-modified anionic micelles for ROS-stimuli response in HeLa cell. Wang QY; Xu YS; Zhang NX; Dong ZP; Zhao BN; Liu LC; Lu T; Wang Y Drug Deliv; 2020 Dec; 27(1):681-690. PubMed ID: 32393138 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]